Comparative Study Between Two Protocols of Rituximab in Pemphigus: About 63 Cases
Journal Title: Journal of Dermatology Research - Year 2023, Vol 4, Issue 2
Abstract
Background: Pemphigus is a rare autoimmune mucocutaneous bullous disease. It includes pemphigus vulgaris and pemphigus superficial. Rituximab is an antibody that targets CD-20 molecules on B-cells and has been approved as a first-line treatment for moderate to severe pemphigus vulgaris. The aim of our study is to evaluate the efficacy and safety of Rituximab in the treatment of pemphigus patients. Materials and methods: It is a prospective study extending over a period of 6 years from December 2016 to July 2022, including all patients with severe or treatment-resistant pemphigus who received treatment with RITUXIMAB at a dose of 375 mg/m2 /week for 4 weeks (lymphoma protocol) or 2 infusions of 1 g at 15-day intervals (rheumatoid arthritis protocol (PR protocol)), combined with oral corticosteroid therapy at a dose of 0.5 to 1 mg/kg/day (depending on severity) with a 6-month taper. Maintenance treatment depends on the IFI level. In the case of high levels, an infusion of 1 g after 6 months is given and in the case of low levels, an infusion of 500 mg after 1 year is given. Consent and authorization from the local ethics committee were required. The data were entered into an Excel program and analyzed via Epi info version 7 software. Patients receiving CNSS health insurance were excluded. Results: 63 patients with pemphigus were using Rituximab (PR protocol: 44 lymphoma protocol: 19), 3 of which are currently being followed up (< 6 months). 44 cases of pemphigus vulgaris of which 15 received the lymphoma protocol and 29 received the PR protocol, 14 cases of superficial pemphigus of which 4 cases received the lymphoma protocol, and 10 cases of PR protocol and 5 cases of vegetative pemphigus received the PR protocol.
Authors and Affiliations
Imane Couissi, Hanane Baybay, Sara El Loudi, Zakia Douhi, Meryem Soughi, Fatima Zahra Mernissi
Keywords
Related Articles
- EP ID EP718594
- DOI https://doi.org/10.46889/JDR.2023.42010
- Views 40
- Downloads 0
Erythema Nodosum Leprosum and Thalidomide: How Effective?
Erythema Nodosum Leprosum (ENL) is considered a distinct entity from the reaction state of leprosy, it is a complication observed during lepromatous leprosy, its occurrence before any antibacillary treatment is possible,...
Post COVID - 19 Infection Diffuse Patch Granuloma Annulare in a Female Patient with Rheumatoid Arthritis: A Case Report
Introduction: Granuloma Annulare (GA) is a benign, usually self-limited, inflammatory granulomatous skin disorder of unknown etiology and with a diversity of clinical variants. Genetic factors, associations with predispo...
Recommendations on Intralymphatic Immunotherapy (ILIT): Precision Medicine in Vaccination and Immunotherapy
Lead Intralymphatic Immunotherapy (ILIT) offers a safe and efficient form of Allergen Immunotherapy (AIT) and is becoming increasingly important in clinical research and off-label use. Since its efficacy depends on pr...
Treatment-Resistant Melasma Response to Oral Tranexamic Acid
Melasma, a common acquired hyperpigmentation disorder primarily affecting facial skin, poses significant therapeutic challenges due to the limited efficacy and potential side effects of available treatments. Tranexamic A...
The Nails in Fine Arts
The observation of the nails represented in art masterpieces encourages to catch details which allow us to suspect skin disorders of the past, still commonly encountered in our daily clinical activity. Nails are cutaneou...